The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma

Nirosha D. Perera, Aaron S. Mansfield

Research output: Contribution to journalReview articlepeer-review


Purpose of Review: For patients with malignant pleural mesothelioma, prognosis is poor with extremely low 5-year survival rates and limited therapeutic options. Here, we review the current treatment landscape for mesothelioma and highlight promising future therapeutic directions. Recent Findings: Evolving frontline therapeutic options for mesothelioma include VEGF inhibition in combination with chemotherapy and dual immune checkpoint inhibition, with synergisms between the therapies and response prediction via biomarkers also being explored. Evolving experimental treatments for mesothelioma include PARP and ALK inhibitors, dendritic and CAR T-cell therapies, anti-mesothelin vaccines, and oncolytic viral therapies, representing timely advances in the field. Summary: The therapeutic landscape for malignant pleural mesothelioma is evolving and preferred treatment in the frontline and later settings will likely evolve with it. However, this does not preclude the evidence for including multi-modal therapies spanning angiogenesis and immune checkpoint inhibitors, and biomarker utilization, in current clinical trials and management.

Original languageEnglish (US)
Pages (from-to)1413-1423
Number of pages11
JournalCurrent oncology reports
Issue number11
StatePublished - Nov 2022


  • CAR T-cell therapy
  • Genetic targets
  • Immunotherapy
  • Malignant pleural mesothelioma
  • Mesothelioma biomarkers
  • VEGF inhibition

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma'. Together they form a unique fingerprint.

Cite this